[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prophylactic-anticoagulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prophylactic-anticoagulation":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100621055","prophylactic-anticoagulation-with-heparine-in-critically-ill-patients-with-renal-impairment-100621055",false,"NCT07365644","Prophylactic ANTicoagulation With HEparine in Critically Ill Patients With Renal Impairment","PANTHER","Inclusion Criteria:\n\n* Presence of impaired renal function (one of the two criteria must be met, both criteria may be met):\n\nGlomerular filtration rate (GFR) \\\u003C30ml\u002Fmin\u002F1.7m² according to the MDRD or CKD-EPI formula.\n\nAcute renal failure (observed or presumed increase in creatinine in the last 7 days) KDIGO stage 3 (creatinine ≥3 times baseline creatinine or ≥354 µmol\u002FL (4 mg\u002FdL) or urine output \\\u003C0.3 mL\u002Fkg\u002Fh for ≥24 hours or initiation of extrarenal clearance or anuria for ≥12 hours)\n\n\\- Expected length of stay in intensive care ≥48 hours\n\nExclusion Criteria:\n\n* Age ≤ 18 years\n* Long-term dialysis patient\n* Current or recent hemorrhage during this hospitalization\n* Patient receiving curative anticoagulation or treated long-term prior to admission with curative anticoagulation.\n* Thrombosis present on admission","ALL","18 Years",{"count":19,"type":20},1111,"ESTIMATED","OBSERVATIONAL","Intensive care patients have an increased risk of venous thromboembolic events (deep vein thrombosis (DVT) and pulmonary embolism (PE)) due to the presence of general risk factors for thrombosis (age, immobilization, obesity, prothrombotic history, etc.), but also risk factors specifically related to their stay in intensive care (sepsis, vasopressors, organ failure, mechanical ventilation, sedation, renal failure, central venous catheters). In addition, these same patients also have an increased risk of hemorrhagic events, mainly associated with coagulation disorders and thrombocytopenia.\n\nGiven this increased risk of thrombosis, it is recommended that heparin thromboprophylaxis be used in intensive care patients in the absence of contraindications.\n\nIn current practice, when faced with a patient with impaired renal function, there is significant heterogeneity in the prescription of thromboprophylaxis between centers and intensive care physicians: some will use enoxaparin, dalteparin, or tinzaparin regardless of renal function, while others will use subcutaneous calciparin or IVSE UFH.\n\nThe PANTHER study is a prospective, multicenter, observational study that aims to evaluate the safety and efficacy of heparin thromboprophylaxis in critically ill patients with renal failure. The goal is to assess whether there is a difference in bleeding risk and thromboprophylaxis efficacy depending on the molecule used.",[24],"Prophylactic Anticoagulation",[26,27,28],"intensive care unit","Prophylactic ANTicoagulation","Renal impairment","NOT_YET_RECRUITING","2026-01-16",{"date":32,"type":33},"2026-01-26","ACTUAL",{"date":35,"type":20},"2026-01-01",{"date":37,"type":20},"2028-02-01",{"name":39,"class":40},"Centre Hospitalier le Mans","OTHER",15]